Antiarrhythmic and electrophysiologic effects of oral propafenone

Eric N. Prystowsky, James J. Heger, Donald A. Chilson, William M. Miles, Joyce Hubbard, Douglas P. Zipes

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Twenty-six patients had ventricular tachycardia initiated at control electrophysiologic study and had a repeat study during oral propafenone therapy. Ten patients had had sustained ventricular tachycardia, 6 cardiac arrest and 10 symptomatic, nonsustained ventricular tachycardia. Twenty-two patients had heart disease, 18 of whom had coronary artery disease. During propafenone therapy, ventricular tachycardia could not be initiated during programmed ventricular stimulation in 5 patients, and in 21 patients the cycle length of induced ventricular tachycardia increased from 246 ± 42 ms at control to 355 ± 96 ms (p <0.001). Seventeen patients were discharged with propafenone therapy and have been followed for a mean of 11 months. No symptomatic ventricular tachycardia recurred in the 5 patients without inducible ventricular tachycardia during drug treatment. Six of 12 patients with inducible ventricular tachycardia during the drug study have remained asymptomatic. In conclusion, propafenone substantially prolongs the cycle length of ventricular tachycardia, and initiation of ventricular tachycardia by programmed ventricular stimulation at drug study does not preclude a favorable clinical outcome.

Original languageEnglish
JournalThe American Journal of Cardiology
Volume54
Issue number9
DOIs
StatePublished - 1984

Fingerprint

Propafenone
Ventricular Tachycardia
Pharmaceutical Preparations
Therapeutics
Heart Arrest
Coronary Artery Disease
Heart Diseases

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Prystowsky, E. N., Heger, J. J., Chilson, D. A., Miles, W. M., Hubbard, J., & Zipes, D. P. (1984). Antiarrhythmic and electrophysiologic effects of oral propafenone. The American Journal of Cardiology, 54(9). https://doi.org/10.1016/S0002-9149(84)80282-9

Antiarrhythmic and electrophysiologic effects of oral propafenone. / Prystowsky, Eric N.; Heger, James J.; Chilson, Donald A.; Miles, William M.; Hubbard, Joyce; Zipes, Douglas P.

In: The American Journal of Cardiology, Vol. 54, No. 9, 1984.

Research output: Contribution to journalArticle

Prystowsky, EN, Heger, JJ, Chilson, DA, Miles, WM, Hubbard, J & Zipes, DP 1984, 'Antiarrhythmic and electrophysiologic effects of oral propafenone', The American Journal of Cardiology, vol. 54, no. 9. https://doi.org/10.1016/S0002-9149(84)80282-9
Prystowsky, Eric N. ; Heger, James J. ; Chilson, Donald A. ; Miles, William M. ; Hubbard, Joyce ; Zipes, Douglas P. / Antiarrhythmic and electrophysiologic effects of oral propafenone. In: The American Journal of Cardiology. 1984 ; Vol. 54, No. 9.
@article{055d3d827e4549ab90c50d776210d9b8,
title = "Antiarrhythmic and electrophysiologic effects of oral propafenone",
abstract = "Twenty-six patients had ventricular tachycardia initiated at control electrophysiologic study and had a repeat study during oral propafenone therapy. Ten patients had had sustained ventricular tachycardia, 6 cardiac arrest and 10 symptomatic, nonsustained ventricular tachycardia. Twenty-two patients had heart disease, 18 of whom had coronary artery disease. During propafenone therapy, ventricular tachycardia could not be initiated during programmed ventricular stimulation in 5 patients, and in 21 patients the cycle length of induced ventricular tachycardia increased from 246 ± 42 ms at control to 355 ± 96 ms (p <0.001). Seventeen patients were discharged with propafenone therapy and have been followed for a mean of 11 months. No symptomatic ventricular tachycardia recurred in the 5 patients without inducible ventricular tachycardia during drug treatment. Six of 12 patients with inducible ventricular tachycardia during the drug study have remained asymptomatic. In conclusion, propafenone substantially prolongs the cycle length of ventricular tachycardia, and initiation of ventricular tachycardia by programmed ventricular stimulation at drug study does not preclude a favorable clinical outcome.",
author = "Prystowsky, {Eric N.} and Heger, {James J.} and Chilson, {Donald A.} and Miles, {William M.} and Joyce Hubbard and Zipes, {Douglas P.}",
year = "1984",
doi = "10.1016/S0002-9149(84)80282-9",
language = "English",
volume = "54",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Antiarrhythmic and electrophysiologic effects of oral propafenone

AU - Prystowsky, Eric N.

AU - Heger, James J.

AU - Chilson, Donald A.

AU - Miles, William M.

AU - Hubbard, Joyce

AU - Zipes, Douglas P.

PY - 1984

Y1 - 1984

N2 - Twenty-six patients had ventricular tachycardia initiated at control electrophysiologic study and had a repeat study during oral propafenone therapy. Ten patients had had sustained ventricular tachycardia, 6 cardiac arrest and 10 symptomatic, nonsustained ventricular tachycardia. Twenty-two patients had heart disease, 18 of whom had coronary artery disease. During propafenone therapy, ventricular tachycardia could not be initiated during programmed ventricular stimulation in 5 patients, and in 21 patients the cycle length of induced ventricular tachycardia increased from 246 ± 42 ms at control to 355 ± 96 ms (p <0.001). Seventeen patients were discharged with propafenone therapy and have been followed for a mean of 11 months. No symptomatic ventricular tachycardia recurred in the 5 patients without inducible ventricular tachycardia during drug treatment. Six of 12 patients with inducible ventricular tachycardia during the drug study have remained asymptomatic. In conclusion, propafenone substantially prolongs the cycle length of ventricular tachycardia, and initiation of ventricular tachycardia by programmed ventricular stimulation at drug study does not preclude a favorable clinical outcome.

AB - Twenty-six patients had ventricular tachycardia initiated at control electrophysiologic study and had a repeat study during oral propafenone therapy. Ten patients had had sustained ventricular tachycardia, 6 cardiac arrest and 10 symptomatic, nonsustained ventricular tachycardia. Twenty-two patients had heart disease, 18 of whom had coronary artery disease. During propafenone therapy, ventricular tachycardia could not be initiated during programmed ventricular stimulation in 5 patients, and in 21 patients the cycle length of induced ventricular tachycardia increased from 246 ± 42 ms at control to 355 ± 96 ms (p <0.001). Seventeen patients were discharged with propafenone therapy and have been followed for a mean of 11 months. No symptomatic ventricular tachycardia recurred in the 5 patients without inducible ventricular tachycardia during drug treatment. Six of 12 patients with inducible ventricular tachycardia during the drug study have remained asymptomatic. In conclusion, propafenone substantially prolongs the cycle length of ventricular tachycardia, and initiation of ventricular tachycardia by programmed ventricular stimulation at drug study does not preclude a favorable clinical outcome.

UR - http://www.scopus.com/inward/record.url?scp=0021716257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021716257&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(84)80282-9

DO - 10.1016/S0002-9149(84)80282-9

M3 - Article

VL - 54

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 9

ER -